[EN] SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES [FR] AGENTS INDUISANT L'APOPTOSE SÉLECTIFS POUR BCL-2 POUR LE TRAITEMENT DU CANCER ET DES MALADIES IMMUNES
本报告描述了镍催化脱羰反应的发展,用于从相应的硫酯合成氟烷基硫醚 (R F SR)。容易获得、便宜且稳定的氟代烷基羧酸 (R F CO 2 H) 作为该转化中的氟代烷基 (R F ) 源。化学计量有机金属研究表明,形成R F -S 键的还原消除是催化循环中的一个具有挑战性的步骤。这导致二苯基膦二茂铁被鉴定为该转化的最佳配体。最终,该方法应用于构建多种氟代烷基硫醚 (R F SR),其中 R = 芳基和烷基。
BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES
申请人:Bruncko Milan
公开号:US20100152183A1
公开(公告)日:2010-06-17
Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.
Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
申请人:Bruncko Milan
公开号:US08563735B2
公开(公告)日:2013-10-22
Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.
BCL-2 SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES
申请人:ABBVIE INC.
公开号:US20130296295A1
公开(公告)日:2013-11-07
Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.
BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
申请人:Bruncko Milan
公开号:US08586754B2
公开(公告)日:2013-11-19
Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.
BCL-2 selective apoptosis-inducing agents for the treatment of cancer and immune diseases
申请人:AbbVie Inc.
公开号:US09073855B2
公开(公告)日:2015-07-07
Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.